Cart
sales@molnova.com
CDK9-IN-10
CAS No. 3542-63-0
CDK9-IN-10( —— )
Catalog No. M26101 CAS No. 3542-63-0
CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 29 | In Stock |
|
| 5MG | 43 | In Stock |
|
| 10MG | 75 | In Stock |
|
| 25MG | 148 | In Stock |
|
| 50MG | 230 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCDK9-IN-10
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
-
DescriptionCDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorE3 Ligase Ligand-Linker Conjugate
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3542-63-0
-
Formula Weight360.365
-
Molecular FormulaC22H16O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (277.50 mM)
-
SMILESOc1cc(OCc2ccccc2)c(O)c2oc(cc(=O)c12)-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chan KH, et al. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem. 2018 Jan 25;61(2):504-513.
molnova catalog
related products
-
FMF-04-159-2
FMF-04-159-2 is a potent, selective, covalent CDK14 inhibitor (IC50=86 nM) with pan-TAIRE family specificity (CDKs 14-18).
-
Cucurbitacin E
Cucurbitacin E is a natural compound which from the climbing stem of Cucumic melo L. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.
-
Ro-3306
Ro-3306 is a potent, selective, ATP-competitive CDK1 inhibitor with Ki of 35 nM against CDK1/cyclin B1, 10-fold selectivity relative to CDK2/cyclin E and >50-fold relative to CDK4/cyclin D.
